VEGF-Targeting Strategies against Diabetic Nephropathy: Obsolete or Still Promising?

Katsuyuki Tanabe* and Jun Wada

Received: January 30, 2018;   Published: February 13, 2018

DOI: 10.26717/BJSTR.2018.02.000758

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Vascular endothelial growth factor (VEGF)-A is well known to be involved in the pathogenesis of diabetic nephropathy. Although it may be a promising therapeutic target, recent evidence that anti-VEGF therapy induces renal thrombotic micro-angiopathy has tempered interest in its use. We discuss the necessary conditions for future VEGF-targeting therapy against diabetic nephropathy.

Keywords: Diabetic nephropathy; VEGF-A; Endothelial dysfunction; Podocytes

Abstract| Introduction| Conclusion| References|